Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STA9090 in Castration-Resistant Prostate Cancer
NCT01368003Phase 2Withdrawn
- Start
- Apr 2011
- Primary completion
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ganetespib in castration-resistant prostate cancer (CRPC). Planned start Apr 2011; status: withdrawn.
02
Drugs
ganetespib
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT01368003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01368003.